Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Roniciclib in Japanese Patients with Advanced Malignancies
NCT02047890Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of roniciclib in solid tumor (2 arms), sponsored by Bayer. Primary endpoints: Number of participants with adverse events as a measure of safety and tolerability at 6 months, Number of participants with abnormal lab parameters at 6 months and 16 more. Started May 2014; status: completed.
02
Drugs
roniciclib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02047890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047890.